Tavexia Lifecare Limited has announced a series of key corporate developments following its Board Meeting on September 7, 2026. The company accepted the resignation of its previous statutory auditors, M/s SSRV & Associates, and appointed M/s DEVAM & Associates LLP as the new auditors, subject to member approval. Additionally, the Board authorized directors to evaluate a potential acquisition of up to 60% equity share capital in Meyonex Pharmaceuticals Limited.
Board Meeting Outcomes
Tavexia Lifecare Limited convened its Board of Directors meeting on Monday, September 7, 2026, to discuss and approve several critical business matters. The meeting, held at the company’s registered office, addressed changes in statutory auditors and strategic expansion opportunities.
New Statutory Auditors Appointed
The Board formally accepted the resignation of M/s SSRV & Associates, Chartered Accountants, as the company’s Statutory Auditors. The firm’s resignation was effective from September 7, 2026. In its place, the Board has approved the appointment of M/s DEVAM & Associates LLP, Chartered Accountants, as the new Statutory Auditors. This appointment is for a term of five consecutive years, commencing from the financial year 2026-27, and is subject to the approval of the company’s members at the upcoming General Meeting.
Strategic Acquisition Under Review
In a significant move towards potential growth, the Board also considered and discussed a proposal for the acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, an unlisted public company. Directors Mr. Chirag Deepak Dedhia and Mr. Sachin Bhanubhai Manseta have been authorized to undertake preliminary evaluation, due diligence, valuation, and negotiations for this proposed transaction. Their mandate includes initiating discussions with Meyonex Pharmaceuticals, negotiating terms, obtaining relevant financial and legal information, and appointing professional advisors for valuation and due diligence.
Other Key Decisions
The Board also approved the re-appointment of Mrs. Khushboo Vasudev as an Independent Director for a second term of five years. Other significant approvals included specific limits for Material Related Party Transactions, taking on record the Secretarial Auditor Report for FY 2025-2026, and adopting the Board Report, Corporate Governance Report, and other financial year-end reports. The company also fixed the date for its 46th Annual General Meeting and the associated book closure period from September 24, 2026, to September 30, 2026.
Source: BSE
